Definium Therapeutics, Inc. (NASDAQ: DFTX) is a Healthcare company (Biotechnology) with a market capitalization of $4.0B. The Maz Rating grades it against the other companies in its sector.
Definium Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $29.38, Definium Therapeutics, Inc. trades at 4.1x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -54.0%, return on invested capital of -25.2% and a free cash flow yield of -4.7%. On the balance sheet: a debt-to-equity ratio of 0.04 and a current ratio of 15.53. Over the past 52 weeks the share price ranged from $12.88 to $49.20, with a beta of 2.21.
Definium Therapeutics, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 12 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.